Anne Ackerman, MD
Urogynecology and Reconstructive Pelvic Surgery · Los Angeles, CANPI 1760610711
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $23,550 of the $31,699 with a category attached, or 74.3%. 15 manufacturers reported payments, led by GSK at 55.8% of the total. 2025 is the largest year on record at $11,180, 3.4 times the $3,306 reported in 2019. Among urogynecology and reconstructive pelvic surgery clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 121 payments — averaging $261.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$18K
- Medtronic$4K
- AbbVie$4K
- Coloplast$2K
- Shionogi Inc$2K
- Boston Scientific$655
- plus $685 from 9 others
Across 6 payments — averaging $1297.34 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Coloplast$4K
- AbbVie$4K
What the payments were for
- Consulting fees$23,55074%
- Grants$1210%
- Travel & lodging$2,1737%
- Food & beverage$5,41717%
- Education$4381%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 5 | $17,678 |
| Medtronic(2 entities) | 62 | $4,172 |
| AbbVie | 9 | $3,995 |
| Coloplast | 18 | $2,415 |
| Shionogi Inc | 1 | $2,100 |
| Boston Scientific | 8 | $655 |
| Urovant Sciences Inc | 3 | $173 |
| Axonics, Inc. | 2 | $141 |
| Astellas Pharma Global Development | 2 | $135 |
| C. R. Bard, Inc. & Subsidiaries | 4 | $85 |
| Applied Medical Resources Corporation | 1 | $46 |
| Astellas Pharma US Inc | 3 | $45 |
| Vertex | 1 | $29 |
| Urogen Pharma, Inc. | 1 | $16 |
| Laborie Medical Technologies Corp. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BOTOX$3,075
- INTERSTIM$3,013
- ALTIS$868
- RESTORELLE$200
- Solyx SIS System$164
- GENERAL FEMALE SUI$152
- Bulkamid$127
- Axonics$127
- GENERAL PELVIC ORGAN PROLAPSE$111
How this compares
$31,699 in reported general payments places this provider in the 90th percentile of 130 urogynecology and reconstructive pelvic surgery providers in California.
See all urogynecology and reconstructive pelvic surgery providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 79 | $75,780 |
| MyrbetriqMirabegron | 30 | $24,361 |
| Estradiol | 41 | $3,013 |
| Tacrolimus | 14 | $2,438 |
| Methenamine Hippurate | 15 | $1,724 |
| Trospium Chloride | 13 | $1,168 |
| Clobetasol Propionate | 15 | $247 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 12 | $114 |
| Oxybutynin Chloride ErOxybutynin Chloride | 13 | $91 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $45 | $24,36130 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 130 urogynecology and reconstructive pelvic surgery providers in California.
Other urogynecology and reconstructive pelvic surgery in Los Angeles
- Tanaz FerzandiLos Angeles$60K
- Christopher TarnayLos Angeles$41K
- Darlene MorrisseyLos Angeles$10K
- Yoko BeanLos Angeles$9K
- Victoria ScottLos Angeles$5K
- Thinh DuongLos Angeles$5K
- Victor VelascoLos Angeles$5K
- Andrey PetrikovetsLos Angeles$5K
- Atieh NovinLos Angeles$5K
- Michele TorosisLos Angeles$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.